1、May 1,2025For release:ImmediatelyRefer to:Ashley Hennessey;gentry_ashley_;(317)416-4363(Media)Mike Czapar;czapar_michael_;(317)617-0983(Investors)Lilly reports first-quarter 2025 financial results and highlights pipeline momentumRevenue in Q1 2025 increased 45%to$12.73 billion driven by volume growt

2、h from Mounjaro and Zepbound.Pipeline progress included positive Phase 3 trial results for orforglipron(small molecule oral GLP-1 agonist)in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.Q1 2025 EPS increased 23%to$3.06 on a reported basis and increased 29%to$3.34 on a no

3、n-GAAP basis,both inclusive of$1.72 of acquired IPR&D charges.Revenue guidance reaffirmed to be between$58.0 billion and$61.0 billion.INDIANAPOLIS,May 1,2025-Eli Lilly and Company(NYSE:LLY)today announced its financial results for the first-quarter of 2025.Lilly had a solid start to the year,with 45

4、%year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound,”said David A.Ricks,Lilly chair and CEO.“Our pipeline continued to deliver across key therapeutic areas,with product approvals in oncology and immunology,and the exciting success of our oral incretin,orforglipron,in the f

5、irst of seven late-stage studies in diabetes and obesity.To support global demand for our newest medicines,were accelerating our manufacturing investments,as underscored by our recent announcement to build four new facilities.Eli Lilly and Company|Lilly Corporate Center|Indianapolis,Indiana 46285|U.

6、S.A.Financial Results$in millions,except per share dataFirst-Quarter20252024%ChangeRevenue$12,728.5$8,768.0 45%Net income Reported 2,759.3 2,242.9 23%Earnings per share Reported 3.06 2.48 23%Net income Non-GAAP 3,004.4 2,335.3 29%Earnings per share Non-GAAP 3.34 2.58 29%A discussion of the non-GAAP